These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22896634)

  • 1. Immune mechanism of the antitumor effects generated by bortezomib.
    Chang CL; Hsu YT; Wu CC; Yang YC; Wang C; Wu TC; Hung CF
    J Immunol; 2012 Sep; 189(6):3209-20. PubMed ID: 22896634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells.
    Kim JE; Jin DH; Lee WJ; Hur D; Wu TC; Kim D
    Pharmacol Res; 2013 May; 71():23-33. PubMed ID: 23428347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells.
    Chen W; Wang J; Shao C; Liu S; Yu Y; Wang Q; Cao X
    Eur J Immunol; 2006 Jun; 36(6):1598-607. PubMed ID: 16708399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma.
    Boozari B; Mundt B; Woller N; Strüver N; Gürlevik E; Schache P; Kloos A; Knocke S; Manns MP; Wirth TC; Kubicka S; Kühnel F
    Gut; 2010 Oct; 59(10):1416-26. PubMed ID: 20675696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome inhibitor bortezomib targeted tumor-endothelial cell interaction in T-cell leukemia/lymphoma.
    Shi WY; Wang L; Xiao D; Yao Y; Yang F; Jiang XX; Leboeuf C; Janin A; Chen SJ; Zhao WL
    Ann Hematol; 2011 Jan; 90(1):53-8. PubMed ID: 20617436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
    Nakata W; Hayakawa Y; Nakagawa H; Sakamoto K; Kinoshita H; Takahashi R; Hirata Y; Maeda S; Koike K
    Int J Oncol; 2011 Dec; 39(6):1529-36. PubMed ID: 21785822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib suppresses the growth of leukemia cells with Notch1 overexpression in vivo and in vitro.
    Huang C; Hu X; Wang L; Lü S; Cheng H; Song X; Wang J; Yang J
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):801-9. PubMed ID: 22996635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines.
    Yamaguchi S; Tatsumi T; Takehara T; Sakamori R; Uemura A; Mizushima T; Ohkawa K; Storkus WJ; Hayashi N
    Cancer; 2007 Oct; 110(7):1469-77. PubMed ID: 17685394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination.
    Tseng CW; Monie A; Wu CY; Huang B; Wang MC; Hung CF; Wu TC
    J Mol Med (Berl); 2008 Aug; 86(8):899-908. PubMed ID: 18542898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Allogeneic dendritic cell vaccine pulsed with heat shocked tumor cell lysate can enhance antitumor immunity].
    You J; Wang CL; Hao XS
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2785-90. PubMed ID: 18167273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
    Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cells loaded with myeloma cells pretreated with a combination of JSI-124 and bortezomib generate potent myeloma-specific cytotoxic T lymphocytes in vitro.
    Jung SH; Lee YK; Lee HJ; Choi NR; Vo MC; Hoang MD; Lim MS; Nguyen-Pham TN; Kim HJ; Lee JJ
    Exp Hematol; 2014 Apr; 42(4):274-81. PubMed ID: 24407159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection.
    Basler M; Lauer C; Beck U; Groettrup M
    J Immunol; 2009 Nov; 183(10):6145-50. PubMed ID: 19841190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
    Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
    J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
    Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
    J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens.
    Huang CY; Chen CA; Lee CN; Chang MC; Su YN; Lin YC; Hsieh CY; Cheng WF
    Gynecol Oncol; 2007 Dec; 107(3):404-12. PubMed ID: 17905417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human tumor cells killed by anthracyclines induce a tumor-specific immune response.
    Fucikova J; Kralikova P; Fialova A; Brtnicky T; Rob L; Bartunkova J; Spísek R
    Cancer Res; 2011 Jul; 71(14):4821-33. PubMed ID: 21602432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
    Liu Y; Huang H; Chen Z; Zong L; Xiang J
    J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
    Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
    Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced efficacy of therapeutic cancer vaccines produced by co-treatment with Mycobacterium tuberculosis heparin-binding hemagglutinin, a novel TLR4 agonist.
    Jung ID; Jeong SK; Lee CM; Noh KT; Heo DR; Shin YK; Yun CH; Koh WJ; Akira S; Whang J; Kim HJ; Park WS; Shin SJ; Park YM
    Cancer Res; 2011 Apr; 71(8):2858-70. PubMed ID: 21368092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.